Market Prospect:

China's in vitro diagnostic industry started in the 1980s, and there is a big gap in the overall technical level of the industry compared with developed countries in Europe and the United States. In recent years, with the rapid growth of downstream demand, domestic enterprises have obtained a good development opportunity, and the trend of accelerated narrowing of the technical gap has been formed.

With the aging of population, increasing insurance coverage and expenditure, income growth and other factors driven, the in vitro diagnostic industry has become one of the most active and fastest growing industries in China and plays an increasing role in the fields of disease prevention, diagnosis and prognosis, therapeutic drug screening and testing, health status evaluation and hereditary prediction.

In 2014, the in vitro diagnostic market size in China was 3.11 billion US dollars, which is expected to reach 8.335 billion US dollars in 2020. From 2014 to 2020, the average annual compound growth rate of in vitro diagnostic market in China was 19.46%, far exceeding the global market average. In terms of the subdivision of diagnostic methods, the diagnostic reagent industry in China has the largest market share of early biochemical diagnosis, but in recent years, immunodiagnosis has gradually exceeded the share of biochemical diagnosis, accounting for more than 50% of the market share in total.

Service of Eastland Group:

As a branch of medical devices, IVD has unique definition and legal supervision. We have been ploughing in the field of IVD for more than ten years to understand the industrial rules and provide targeted solutions and services.